Jacqueline N Chu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7798619/publications.pdf

Version: 2024-02-01

1684129 1199563 23 166 5 12 citations g-index h-index papers 23 23 23 207 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Foundations of gastrointestinal-based drug delivery and future developments. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 219-238.	17.8	66
2	Personalized Radiation Attenuating Materials for Gastrointestinal Mucosal Protection. Advanced Science, 2021, 8, 2100510.	11.2	3
3	Endoscopic techniques for the management of bariatric surgical adverse events. Gastrointestinal Endoscopy, 2021, 93, 994-995.	1.0	O
4	Thinking green: modelling respirator reuse strategies to reduce cost and waste. BMJ Open, 2021, 11, e048687.	1.9	12
5	Management of Peptic Strictures. American Journal of Gastroenterology, 2021, 116, 427-428.	0.4	O
6	Patient and Health Care Worker Perceptions of Communication and Ability to Identify Emotion When Wearing Standard and Transparent Masks. JAMA Network Open, 2021, 4, e2135386.	5.9	7
7	Detachable snare to prevent postpolypectomy bleeding. VideoGIE, 2020, 5, 510-512.	0.7	1
8	Prospective Evaluation of the Transparent, Elastomeric, Adaptable, Long-Lasting (TEAL) Respirator. ACS Pharmacology and Translational Science, 2020, 3, 1076-1082.	4.9	6
9	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. Journal of Oncology, 2020, 2020, 1-10.	1.3	10
10	Case 3-2020: A 44-Year-Old Man with Weight Loss, Diarrhea, and Abdominal Pain. New England Journal of Medicine, 2020, 382, 365-374.	27.0	3
11	Costâ€effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer. Cancer, 2019, 125, 278-289.	4.1	24
12	Flu vaccination rate of patients with severe immune-related adverse events Journal of Clinical Oncology, 2019, 37, e18234-e18234.	1.6	1
13	Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis Journal of Clinical Oncology, 2019, 37, e15517-e15517.	1.6	0
14	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 392-400.e7.	4.4	17
15	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience Journal of Clinical Oncology, 2018, 36, 3060-3060.	1.6	4
16	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance Journal of Clinical Oncology, 2018, 36, 3096-3096.	1.6	4
17	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	1
18	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis Journal of Clinical Oncology, 2018, 36, 829-829.	1.6	0

#	Article	IF	CITATIONS
19	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers Journal of Clinical Oncology, 2018, 36, e16089-e16089.	1.6	0
20	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer Journal of Clinical Oncology, 2018, 36, e15134-e15134.	1.6	0
21	The Reply. American Journal of Medicine, 2016, 129, e101.	1.5	O
22	South Sudan to Martha's Vineyard: Malaria. American Journal of Medicine, 2016, 129, 163-166.	1.5	3
23	Influence of providers and nurses on completion of non-targeted HIV screening in an urgent care setting. AIDS Research and Therapy, 2014, 11, 24.	1.7	4